Medexus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	99.43	108.33	113.05	108.1	76.7	79.66
Revenue Growth (YoY)	-9.23%	-4.18%	4.59%	40.93%	-3.72%	43.52%
Cost of Revenue	36.44	44.82	47.99	42.33	33.03	32.18
Gross Profit	63	63.51	65.07	65.77	43.67	47.48
Selling, General & Admin	47.47	43.18	44.87	48.25	44.03	36.17
Research & Development	1.92	1.23	1.61	2.94	5.87	4.6
Amortization of Goodwill & Intangibles	9.43	6.93	5.56	5.73	5.75	5.47
Operating Expenses	59.11	51.59	52.28	57.28	56.05	46.75
Operating Income	3.89	11.92	12.79	8.49	-12.38	0.73
Interest Expense	-6.18	-8.2	-13.36	-13.61	-12.22	-9.82
Currency Exchange Gain (Loss)	-	-	-	-1.69	-0.15	1.99
Other Non Operating Income (Expenses)	3.42	1.41	2.68	2.64	23.55	-22.3
EBT Excluding Unusual Items	1.13	5.14	2.1	-4.17	-1.2	-29.39
Merger & Restructuring Charges	-0.82	-0.9	-1.11	-0.88	-0.87	-2.11
Asset Writedown	-0.34	-2.8	-0.89	-	-1.75	-
Pretax Income	-0.03	1.44	0.11	-5.04	-3.82	-31.5
Income Tax Expense	0.25	-0.81	0.32	-6.26	-0.94	-3.24
Net Income	-0.27	2.25	-0.21	1.22	-2.88	-28.26
Net Income to Common	-0.27	2.25	-0.21	1.22	-2.88	-28.26
Shares Outstanding (Basic)	32	26	22	20	19	15
Shares Outstanding (Diluted)	32	27	22	21	20	15
Shares Change (YoY)	28.99%	18.76%	8.76%	3.36%	30.65%	5.83%
EPS (Basic)	-0.01	0.09	-0.01	0.06	-0.15	-1.86
EPS (Diluted)	-0.01	0.08	-0.01	0.06	-0.15	-1.86
Free Cash Flow	17.16	23.85	18.66	-1.51	-1.28	4.92
Free Cash Flow Per Share	0.54	0.90	0.84	-0.07	-0.06	0.32
Gross Margin	63.35%	58.62%	57.56%	60.84%	56.94%	59.60%
Operating Margin	3.91%	11.00%	11.31%	7.85%	-16.13%	0.92%
Profit Margin	-0.27%	2.07%	-0.19%	1.13%	-3.75%	-35.48%
Free Cash Flow Margin	17.26%	22.02%	16.51%	-1.39%	-1.67%	6.18%
EBITDA	13.44	18.94	18.44	14.37	-6.46	6.35
EBITDA Margin	13.52%	17.48%	16.31%	13.30%	-8.42%	7.98%
D&A For EBITDA	9.55	7.02	5.66	5.88	5.92	5.62
EBIT	3.89	11.92	12.79	8.49	-12.38	0.73
EBIT Margin	3.91%	11.00%	11.31%	7.85%	-16.13%	0.92%
Effective Tax Rate	-	-	301.89%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.